GlassScriptPhysician profile
Shari A Brazinsky
NPI 1245339340
$82,213.79
in general payments reported to CMS, 2019-2025
45 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,558 · 2020: $16K · 2021: $12K · 2022: $36K · 2023: $8,053.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $6,773 · Travel and Lodging: $921 · Food and Beverage: $359.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $6,773.00 |
| Travel and Lodging | $921.02 |
| Food and Beverage | $359.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $74,217.03 | 2019-2023 | Trelegy Ellipta, Nucala |
| Astrazeneca Pharmaceuticals LP | $2,215.71 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $967.11 | 2019-2023 | Ofev |
| Regeneron Healthcare Solutions, INC. | $782.63 | 2019-2023 | Dupixent |
| Amgen INC. | $652.65 | 2020-2023 | Tezspire |
| Actelion Pharmaceuticals US, INC. | $444.05 | 2019-2023 | Opsumit, Uptravi |
| Genzyme Corporation | $377.58 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $318.00 | 2019-2021 | |
| Pfizer INC. | $232.49 | 2019-2022 | |
| Insmed, INC. | $229.34 | 2019-2023 | Arikayce |
| Philips North America LLC | $204.24 | 2019-2022 | |
| Mylan Specialty L.P. | $203.06 | 2019-2023 | Yupelri |
| Paratek Pharmaceuticals, INC. | $134.60 | 2020-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $129.92 | 2021-2022 | |
| Genentech USA, INC. | $115.96 | 2019-2022 |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $113.08 | 2021-2022 | |
| United Therapeutics Corporation | $100.00 | 2020 | |
| Grifols USA, LLC | $90.15 | 2019-2022 | |
| Sanofi Pasteur INC. | $88.53 | 2019-2022 | |
| Harmony Biosciences LLC | $60.11 | 2022 | |
| Janssen Pharmaceuticals, INC | $50.58 | 2021 | |
| Advanced Respiratory, INC | $49.80 | 2020-2021 | |
| Electromed, INC. | $44.65 | 2022 | |
| Hospira, INC. | $44.03 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $36.26 | 2020-2021 | |
| Resmed Corp | $35.97 | 2019 | |
| Medline Industries LP | $28.34 | 2021 | |
| Shionogi INC | $26.27 | 2021 | |
| Daiichi Sankyo INC. | $26.07 | 2022 | |
| Circassia INC. | $25.68 | 2019 | |
| Melinta Therapeutics, LLC | $21.10 | 2022 | |
| Pulmonx Corporation | $19.06 | 2020 | |
| Vyera Pharmaceuticals, LLC | $18.74 | 2020 | |
| Inogen, INC. | $18.59 | 2019 | |
| Pentax of America, INC. | $18.39 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $16.91 | 2019 | |
| Jazz Pharmaceuticals INC. | $16.25 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $14.45 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.27 | 2019 | |
| Allergan, INC. | $13.14 | 2020 |
5 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shari Brazinsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.